<?xml version="1.0" encoding="UTF-8"?>
<p id="Par29">3. PPAR gamma activators. Peroxisome proliferator-activated receptors (PPARs) are key regulators of inflammation and lipid metabolism, their activation results specifically in a reduction in inflammatory cytokines (as IL6, INF γ) [
 <xref ref-type="bibr" rid="CR40">40</xref>]. Rosiglitazone and pioglitazone (two PPARγ agonists) are insulin-mimetic drugs used in type 2 diabetes with high overall potential in reducing influenza virus infection [
 <xref ref-type="bibr" rid="CR40">40</xref>]. Pioglitazone seems to suppress inflammation by reducing MCP-1 expression, an important mediator of host inflammation [
 <xref ref-type="bibr" rid="CR40">40</xref>]. Pioglitazone was shown to increase survival of infected mice up to 40%, and the benefit may be attributed to modulation of subject inflammatory response [
 <xref ref-type="bibr" rid="CR40">40</xref>, 
 <xref ref-type="bibr" rid="CR41">41</xref>]. The combination of pioglitazone and AICAR increase survival of infected mice from 30 up to 100% [
 <xref ref-type="bibr" rid="CR41">41</xref>]. Therefore, metformin, AICAR and PPARγ agonists, in combination or alone, might be studied and then used in the treatment of severe influenza in association with other antiviral/immunomodulatory drugs in the future. 
</p>
